subscribeSubscribe
Relief Announces Six-Month Stability Data on a New Formulation of RLF-100

Relief Announces Six-Month Stability Data on a New Formulation of RLF-100
ACCESSWIRE
07 Nov 2022
Share Share
Relief Therapeutics Announces Promising Initial Stability Data on RLF-100(R)

Relief Therapeutics Announces Promising Initial Stability Data on RLF-100(R)
ACCESSWIRE
03 Aug 2022
Share Share
Déjà vu: FDA rejects NRx filing for emergency use in COVID-19

Déjà vu: FDA rejects NRx filing for emergency use in COVID-19
Nick Paul Taylor FIERCEBIOTECH
02 Jul 2022
Share Share
NRx Pharma Provides Update on BTD Request for ZYESAMI

NRx Pharma Provides Update on BTD Request for ZYESAMI
PRNEWSWIRE
10 Jun 2022
Share Share
NRx to halt analysis of Zyesami for critical Covid-19 due to futility

NRx to halt analysis of Zyesami for critical Covid-19 due to futility
CLINICALTRIALSARENA
27 May 2022
Share Share
NRx tanks as peptide fails NIH trial in severe COVID-19 patients

NRx tanks as peptide fails NIH trial in severe COVID-19 patients
N.P. Taylor FIERCEBIOTECH
27 May 2022
Share Share
NRx Pharma Files New Breakthrough Therapy Designation Request for ZYESAMI®

NRx Pharma Files New Breakthrough Therapy Designation Request for ZYESAMI®
PRNEWSWIRE
21 Apr 2022
Share Share
I-SPY COVID Trial Suggests No Benefit with Addition of Nebulized ZYESAMI

I-SPY COVID Trial Suggests No Benefit with Addition of Nebulized ZYESAMI
PRNEWSWIRE
31 Mar 2022
Share Share
NRx Pharma Expand ZYESAMI US Access and Right to Try Programs

NRx Pharma Expand ZYESAMI US Access and Right to Try Programs
GLOBENEWSWIRE
18 Jan 2022
Share Share
NRx seeks breakthrough therapy designation for Covid-19 treatment

NRx seeks breakthrough therapy designation for Covid-19 treatment
PHARMACEUTICAL-TECHNOLOGY
29 Dec 2021
Share Share